Hookipa Pharma Inc. is looking to raise about $50 million in a public offering to further advance its lead immunotherapy candidate, HB-200, into a pivotal phase III trial in combination with Keytruda (pembrolizumab, Merck & Co. Inc.) for the first-line treatment of recurrent or metastatic head and neck cancer associated with human papillomavirus (HPV) 16.

Biopharmas raising money in public or private financings, including: Effector, Lexicon, Lyra, Oculis, Phion, Pneumagen.

Med-tech firms raising money in public or private financings, including: Boston Scientific.

Biopharmas raising money in public or private financings, including: Anocca, Belite, Cybin, Lynk, Phio, Violet.

Med-tech firms raising money in public or private financings, including: Encare, Revamp Medical.

Heartseed Inc. raised ¥2 billion (US$14.3 million) in a series D round to continue the phase I/II Lapis trial of its allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocytes for heart failure. The lead asset, HS-001, is an investigational cell therapy consisting of clusters of purified heart muscle cells (cardiomyocyte spheroids) derived from iPSCs that are designed to restore heart muscle and function in patients with advanced heart failure.

Biopharmas raising money in public or private financings, including: Alpha Cognition, Biodexa, Defence, Dermata, Mydecine, Oculis, Rakovina.

Heartseed Inc. raised ¥2 billion (US$14.3 million) in a series D round to continue the phase I/II Lapis trial of its allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocytes for heart failure. The lead asset, HS-001, is an investigational cell therapy consisting of clusters of purified heart muscle cells (cardiomyocyte spheroids) derived from iPSCs that are designed to restore heart muscle and function in patients with advanced heart failure.

Biopharmas raising money in public or private financings, including: Agile, Aptose, Carmot, Effector, Lyra, Tscan, Vivoryon.